ERBB2 and breast carcinoma: Another derivative of the CDM, namely the tumor burden model (Table 2), was initially developed to characterize the antitumor effects of trastuzumab-mertansine (T-DM1), an antibody–drug conjugate for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer [94].